[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
…, C Sidiropoulou, G Adamis, A Fragkou… - The Lancet …, 2021 - thelancet.com
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
…, S Metallidis, G Adamis, K Tsiakos, A Fragkou… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
[HTML][HTML] Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the …
…, E Christaki, S Metallidis, G Adamis, A Fragkou… - …, 2023 - thelancet.com
Background The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or …
Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled …
…, S Metallidis, G Adamis, K Tsiakos, A Fragkou… - Nature Medicine, 2021 - nature.com
… Archontoula Fragkou … Archontoula Fragkou & Spyridon Savvanis … Archontoula Fragkou …
[HTML][HTML] Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia
…, V Petrakis, G Adamis, NK Gatselis, A Fragkou… - Cytokine, 2023 - Elsevier
Objectives Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR)
predict progression to severe respiratory failure (SRF) or death among patients with …
predict progression to severe respiratory failure (SRF) or death among patients with …
Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor
…, S Metallidis, G Adamis, K Tsiakos, A Fragkou… - medRxiv, 2021 - medrxiv.org
Background In a previous open-label trial, early anakinra treatment guided by elevated
soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 …
soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 …
[HTML][HTML] Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled …
…, H Milionis, S Metallidis, M Astriti, A Fragkou… - Critical Care, 2024 - Springer
Background Endotype classification may guide immunomodulatory management of patients
with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions …
with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions …
Glycemic and lipid profile of patients with COVID-19: Impact on morbidity and mortality
…, K Komnianou, P Grigoropoulou, A Fragkou… - Clinical Nutrition …, 2023 - Elsevier
Introduction Recent studies have shown that patients with COVID-19, who have underlying
diabetes mellitus, develop a severe clinical course and have increased mortality. Similarly, …
diabetes mellitus, develop a severe clinical course and have increased mortality. Similarly, …
Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE Trial
…, E Christaki, S Metallidis, G Adamis, A Fragkou… - 2022 - papers.ssrn.com
Background: The SAVE-MORE trial demo that anakinra treatment in COVID-19 pneumonia
with plasma suPAR (soluble urokinase plasminogen activator) 6ng/ml or more was …
with plasma suPAR (soluble urokinase plasminogen activator) 6ng/ml or more was …
Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID Syndrome
…, K Akinosoglou, H Milionis, A Fragkou… - 2022 - papers.ssrn.com
We studied whether progression of severe pneumonia into post-acute COVID-19 syndrome (PACS)
is associated with long-term immune dysregulation. Patients with known history of …
is associated with long-term immune dysregulation. Patients with known history of …
